Sareum Holdings (SAR)

 

SAR Share PerformanceMore

52 week high1.2375 20/02/17
52 week low0.7000 29/11/17
52 week change -0.2270 (-18.92%)
4 week volume119,228,063 25/01/18
price0.9730
price date1519138707
close0.9750

Latest NewsMore

Notice of Interim Results

Notification of the date financial results will be published

Issue of Options

RNS Number: 9211Z Sareum Holdings PLC 20 December 2017 (AIM: SAR) 20 December 2017 SAREUM HOLDINGS PLC ("Sareum" or the "Company") Issue of Options The Company announces that it granted on 19 December 2017 the following share options (the "Options") to Dr Tim Mitchell, Chief Executive Officer, Dr John Reader, Chief Scientific Officer and ...

Sareum announces new patent approval

Sareum announced that the Japanese Patent Office granted a patent for inventions associated with Sareum's TYK2 kinase ...

Patent Grants in Japan & China for TYK2 Inhibitors

RNS Number: 6985Z Sareum Holdings PLC 19 December 2017 (AIM: SAR) 19 December 2017 SAREUM HOLDINGS PLC ("Sareum" or "the Company") Patent Grants in Japan and China for Sareum's TYK2 Inhibitors Sareum (AIM: SAR), the specialist cancer drug discovery and development business, is pleased to announce that the Japanese Patent Office has grante...

Result of AGM

RNS Number: 3728Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") Results of AGM Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, advises that it held its Annual General Meeting today and all resolutions were duly passed. -Ends- For furth...

Sareum reports 'significant' year of progress

Sareum Holdings, a cancer drug discovery and development business, said it has seen a year of significant progress. Its lead...

AGM Statement

RNS Number: 2254Z Sareum Holdings PLC 14 December 2017 (AIM: SAR) 14 December 2017 Sareum Holdings plc ("Sareum" or "the Company") AGM Statement Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, will be holding its Annual General Meeting today, at 10:00 at the offices of Citigate Dewe Rogerson, 3 Londo...

Notice of AGM and Annual Report & Accounts

RNS Number: 8386W Sareum Holdings PLC 20 November 2017 (AIM: SAR) 20 November 2017 Sareum Holdings plc ("Sareum" or "the Company") Notice of AGM and Annual Report & Accounts Sareum Holdings plc (AIM: SAR), the specialist cancer drug discovery and development business, has notified its shareholders that its Annual General Meeting ("AGM") w...

Fundamental DataMore

P/E ratio48.65
EPS0.02
Dividend yield0 %

Latest discussion posts More

  • Well worth reading

    https://www.biocentury.com/biocentury/regulation/2017-12-15/how-fda?s-regenerative-medicine-framework-puts-us-japan-and-
    17-Dec-2017
    fredd1eboy
  • Re: Good progress & maiden profits

    http://uk.advfn.com/p.php?pid=chartscreenshotshow&u=CTcwOoFJTTlWkejW+geWUhtoFp3NOSgnWPFmM8wjkZQ= Posted this chart in October - been waiting for 0.75p entry price since then ...
    16-Nov-2017
    KALAN
  • Re: Another 200% up....

    Cornhill had this for a week .
    15-Nov-2017
    Ripley94

Users' HoldingsMore

Users who hold Sareum Holdings also hold..

Codes & Symbols

ISINGB00B02RFS12
SymbolsSAR, LSE:SAR, SAR.L, SAR:LN, LON:SAR, XLON:SAR

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account